DILON Diagnostics and GE Healthcare are pleased to announce that they have signed an agreement for DILON to be the exclusive distributor of GE's Discovery NM750b Molecular Breast Imaging system in North America. The signing of this exclusive agreement brings closer together two significant players in Molecular Breast Imaging. Last year, GE Healthcare and DILON Diagnostics signed a global distribution agreement in select world markets.
The Discovery NM750b breast imaging system offers clinicians an important tool for imaging of a broad range of patients, including those with dense breasts who may be at higher risk for breast cancer. The power of functional imaging to see early changes is a key factor in early detection in breast cancer.
"We are very pleased to continue collaborating with GE Healthcare, a world leader in innovation, in the fight against breast cancer. The relationship with GE Healthcare will enable us to offer a complete spectrum of BSGI/MBI solutions through our established sales channels in breast cancer diagnostics and surgery," says Robert G. Moussa, DILON Diagnostics Chairman and CEO. Nathan Hermony, Nuclear Imaging global business manager for GE Healthcare, added that "GE believes strongly in this advanced technology and the potential for this type of imaging to improve breast cancer diagnosis. DILON Diagnostics will further the education and acceptance of Molecular Breast Imaging."